Factor viii sequences
US-2017049859-A1 · Feb 23, 2017 · US
Methods of delivering factor VIII encoding nucleic acid sequences
US10124041B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10124041-B2 |
| Application number | US-201615254984-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 1, 2016 |
| Priority date | Jun 12, 2012 |
| Publication date | Nov 13, 2018 |
| Grant date | Nov 13, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
There is provided a nucleic acid molecule comprising a nucleotide sequence encoding a factor VIII protein, wherein a B domain portion of the factor VIII protein is encoded by a nucleotides sequence between 90 and 111 nucleotides in length and has an amino acid sequence that is at least 85% identical to SEQ ID NO: 4 which comprises six asparagine residues. Also provided is a factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating Haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for administering to a subject a nucleic acid molecule encoding a Factor VIII protein, comprising: intravenously administering to the subject a nucleic acid molecule encoding a Factor VIII protein, wherein the Factor VIII protein B domain comprises a spacer that is replaced and wherein the B domain comprises the amino acid sequence set forth in SEQ ID NO:4. 2. The method of claim 1 , wherein the B domain of said Factor VIII protein is between 30 and 37 amino acids in length. 3. The method of claim 1 , wherein the B domain of said Factor VIII protein is 31 amino acids in length. 4. The method of claim 1 , wherein the B domain of said Factor VIII protein comprises the amino acid sequence of SEQ ID NO:5. 5. The method of claim 1 , wherein the B domain of said Factor VIII protein consists of the amino acid sequence of SEQ ID NO:5. 6. The method of claim 1 , wherein the Factor VIII protein encoded by the nucleic acid molecule comprises domains A1, A2, A3, C1 and C2, and wherein the nucleic acid molecule is codon optimised compared to a corresponding wild type sequence. 7. The method of claim 1 , wherein said Factor VIII protein comprises the amino acid sequence of SEQ ID NO:6. 8. The method of claim 1 , wherein said nucleic acid molecule encoding said Factor VIII protein comprises the nucleic acid sequence of SEQ ID NO:3.
Assignees
Inventors
Classifications
Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)} · CPC title
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title
Murine · CPC title
Animal expressing industrially exogenous proteins · CPC title
Genetically modified vertebrates, e.g. transgenic · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10124041B2 cover?
- There is provided a nucleic acid molecule comprising a nucleotide sequence encoding a factor VIII protein, wherein a B domain portion of the factor VIII protein is encoded by a nucleotides sequence between 90 and 111 nucleotides in length and has an amino acid sequence that is at least 85% identical to SEQ ID NO: 4 which comprises six asparagine residues. Also provided is a factor VIII protein,…
- Who is the assignee on this patent?
- Ucl Business Plc, St Jude Childrens Res Hospital
- What technology area does this patent fall under?
- Primary CPC classification A61K38/37. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).